AR063470A1 - Terapia combinada - Google Patents

Terapia combinada

Info

Publication number
AR063470A1
AR063470A1 ARP070103423A ARP070103423A AR063470A1 AR 063470 A1 AR063470 A1 AR 063470A1 AR P070103423 A ARP070103423 A AR P070103423A AR P070103423 A ARP070103423 A AR P070103423A AR 063470 A1 AR063470 A1 AR 063470A1
Authority
AR
Argentina
Prior art keywords
inhibitor
effective amount
combination
vla
radiotherapy
Prior art date
Application number
ARP070103423A
Other languages
English (en)
Inventor
Gary Bridger
Louis M Pelus
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of AR063470A1 publication Critical patent/AR063470A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Métodos para movilizar células progenitoras y/o células madre de la médula espinal hacia el flujo sanguíneo administrando una combinacion de al menos un inhibidor de CXCR4 (como por ejemplo AMD3100), y al menos un inhibidor de VLA4, (como por ejemplo AMD15057). Las combinaciones también se pueden usar para el tratamiento del mieloma multiple. Reivindicacion 9: Un método para aumentar la efectividad de un tratamiento quimioterapéutico o una radioterapia en un sujeto que padece una malignidad hematopoyética o mieloide, caracterizado porque dicho método comprende administrar dicho tratamiento quimioterapéutico o radioterapia a dicho sujeto junto con una cantidad efectiva de al menos un inhibidor de CXCR4 en combinacion con una cantidad efectiva de al menos un inhibidor de VLA-4 o en combinacion con una cantidad efectiva de por lo menos un agonista de CXCR2. Reivindicacion 17: Una composicion caracterizada porque comprende como ingredientes activos al menos un inhibidor de CXCR4 y al menos un inhibidor de VLA-4 junto con un excipiente farmacéutico o veterinario.
ARP070103423A 2006-08-02 2007-08-02 Terapia combinada AR063470A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83529006P 2006-08-02 2006-08-02

Publications (1)

Publication Number Publication Date
AR063470A1 true AR063470A1 (es) 2009-01-28

Family

ID=38997866

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103423A AR063470A1 (es) 2006-08-02 2007-08-02 Terapia combinada

Country Status (12)

Country Link
US (1) US20100003224A1 (es)
EP (1) EP2068868A2 (es)
JP (1) JP2009545620A (es)
CN (1) CN101495115A (es)
AR (1) AR063470A1 (es)
AU (1) AU2007281090A1 (es)
BR (1) BRPI0714799A2 (es)
CA (1) CA2659463A1 (es)
IL (1) IL196556A0 (es)
MX (1) MX2009001272A (es)
RU (1) RU2009107030A (es)
WO (1) WO2008017025A2 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2426139B1 (en) 2002-08-27 2014-10-01 Biokine Therapeutics Ltd. CXCR4 antagonist and use thereof
WO2008075370A2 (en) 2006-12-21 2008-06-26 Biokine Therapeutics Ltd. T-140 peptide analogs having cxcr4 super-agonist activity for cancer therapy
US9427456B2 (en) 2009-06-14 2016-08-30 Biokine Therapeutics Ltd. Peptide therapy for increasing platelet levels
WO2012034194A1 (en) * 2010-09-17 2012-03-22 Antisense Therapeutics Ltd Method for mobilizing stem and/or progenitor cells
EP2685971A2 (en) * 2011-03-18 2014-01-22 University Of Virginia Patent Foundation Compositions and methods for tissue engineering and cell based therapies
JP2014513727A (ja) 2011-05-16 2014-06-05 ジェンザイム・コーポレーション Ｃｘｃｒ４拮抗薬の使用
WO2012174522A1 (en) * 2011-06-16 2012-12-20 Children's Medical Center Corporation Combined chemical modification of sphingosine-1-phosphate (s1p) and cxcr4 signalling pathways for hematopoietic stem cell (hsc) mobilization and engraftment
EP2841084B1 (en) 2012-04-24 2018-05-30 Biokine Therapeutics Ltd. Cxcr4 antagonist peptide for use in the treatment of large cell lung cancer
KR20170105514A (ko) * 2014-12-12 2017-09-19 커먼웰쓰 사이언티픽 앤 인더스트리알 리서치 오거니제이션 알파 9 인테그린 길항제 및 cxcr4 길항제를 사용한 hsc의 이탈 및 방출
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
JP6676182B2 (ja) 2016-02-23 2020-04-08 バイオラインアールエックス・リミテッドＢｉｏＬｉｎｅＲｘ Ｌｔｄ． 急性骨髄性白血病の治療方法
MX2018012250A (es) * 2016-04-08 2019-06-24 Syros Pharmaceuticals Inc Agonistas de los receptores de acido retinoico alfa (rara) para el tratamiento de leucemia mieloide aguda (aml) y sindrome mielodisplasico (mds).
WO2018085574A2 (en) * 2016-11-02 2018-05-11 Washington University Compositions comprising an integrin inhibitor and agents which interact with a chemokine and methods of use thereof
TWI734027B (zh) * 2017-09-18 2021-07-21 泰宗生物科技股份有限公司 用於治療癌症之組合物
WO2019113375A2 (en) * 2017-12-06 2019-06-13 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
US11260079B2 (en) 2017-12-06 2022-03-01 Magenta Therapeutics, Inc. Dosing regimens for the mobilization of hematopoietic stem and progenitor cells

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001826A (en) * 1989-12-21 1999-12-14 Anormed, Inc. Chemical compounds
US5021409A (en) * 1989-12-21 1991-06-04 Johnson Matthey Plc Antiviral cyclic polyamines
GB9126677D0 (en) * 1991-12-16 1992-02-12 Johnson Matthey Plc Improvements in chemical compounds
EP1378522A3 (en) * 1993-06-08 2004-02-04 SmithKline Beecham Corporation Methods of enhancing bioactivity of chemokines
US6447766B1 (en) * 1993-06-08 2002-09-10 Smithkline Beecham Corporation Method of mobilizing hematopoietic stem cells
US5510332A (en) * 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
UA44901C2 (uk) * 1994-08-19 2002-03-15 Акцо Нобел Н.В. Оптично анізотропний розчин, спосіб його одержання, спосіб виготовлення целюлозних екструдатів, целюлозне волокно, гумовий виріб та шина транспортного засобу
US6506770B1 (en) * 1996-06-06 2003-01-14 Anormed, Inc. Antiviral compounds
US5968546A (en) * 1997-05-16 1999-10-19 Baur; Marcus Keratinocyte culture from precursor cells
PL198189B1 (pl) * 1998-05-28 2008-06-30 Biogen Idec Ma (R)-N-{[4-{[(2-metylofenyloamino)-karbonylo]amino}fenylo]acetylo}-L-prolilo-3-metylo]-ß-alanina, jej zastosowanie i kompozycja farmaceutyczna ją zawierająca
US6365583B1 (en) * 1999-02-02 2002-04-02 Anormed, Inc. Methods to enhance white blood cell count
US6750348B1 (en) * 1999-03-24 2004-06-15 Anormed, Inc. Chemokine receptor binding heterocyclic compounds
JP2003506491A (ja) * 1999-08-13 2003-02-18 バイオジェン インコーポレイテッド 細胞接着インヒビター
US6667320B2 (en) * 1999-12-17 2003-12-23 Anormed Chemokine receptor binding heterocyclic compounds
MXPA03002326A (es) * 2000-09-15 2003-06-06 Anormed Inc Compuestos heterociclicos de union de receptor de quimocina.
JP2004508421A (ja) * 2000-09-15 2004-03-18 アノーメッド　インコーポレイティド ケモカインレセプター結合性ヘテロ環式化合物
CA2421796A1 (en) * 2000-09-15 2002-05-02 Anormed Inc. Chemokine receptor binding heterocyclic compounds
NZ524580A (en) * 2000-09-29 2004-10-29 Anormed Inc Process for preparation of N-1 protected N ring nitrogen containing cyclic polyamines and products thereof
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
CN101941964A (zh) * 2003-04-22 2011-01-12 阿诺麦德股份有限公司 具有促进功效的趋化因子受体结合的杂环化合物
US7501518B2 (en) * 2003-04-22 2009-03-10 Genzyme Corporation Methods of making 2,6-diaryl piperidine derivatives
EP1708703A4 (en) * 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS
US7332605B2 (en) * 2004-03-15 2008-02-19 Anormed, Inc. Process for the synthesis of CXCR4 antagonist
WO2006020891A2 (en) * 2004-08-13 2006-02-23 Anormed Inc. Chemokine combinations to mobilize progenitor/stem cells
WO2006116185A2 (en) * 2005-04-25 2006-11-02 Cbr Institute For Biomedical Research, Inc. Methods for the treatment of multiple myeloma

Also Published As

Publication number Publication date
MX2009001272A (es) 2009-02-11
US20100003224A1 (en) 2010-01-07
CA2659463A1 (en) 2008-02-07
JP2009545620A (ja) 2009-12-24
AU2007281090A1 (en) 2008-02-07
BRPI0714799A2 (pt) 2013-05-21
IL196556A0 (en) 2009-11-18
RU2009107030A (ru) 2010-09-10
WO2008017025A3 (en) 2008-10-09
CN101495115A (zh) 2009-07-29
WO2008017025A2 (en) 2008-02-07
EP2068868A2 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
AR063470A1 (es) Terapia combinada
AR109605A2 (es) Método para tratar enfermedades vasculares periféricas, composición y utilización
AR062271A1 (es) Uso de una cantidad efectiva de al menos un inhibidor de cxcr4, al menos un agonista de cxcr2 y g-csf para movilizar las celulas progenitoras y/o celulas madre
ECSP10010589A (es) Farmaco contra el cancer de higado
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
CO6331301A2 (es) Combinaciones y metodos para administracion subcutanea de inmunoglobulina y hialuronidasa
AR049955A1 (es) Composiciones y metodos para el tratamiento de trastornos metabolicos
UY28081A1 (es) Administracinn combinada de una indolinona con un agente quimioterapcutico para trastornos de proliferacinn celular
TN2012000270A1 (en) Methods and low dose regimens for treating red blood cell disorders
AR044007A1 (es) Metodos para el tratamiento de la enfermedad de parkinson
AR060089A1 (es) Tratamiento del dolor
AR060306A1 (es) Terapia de combinacion de anticuerpos contra ctla4
CO5670356A2 (es) Programa de dosificaicon para un nuevo agente anticanceroso
WO2011041478A8 (en) Hematopoietic stem cells for use in the treatment of a kidney injury
BR0111800A (pt) Combinações de inibidores de depeptidil peptidase iv e outros agentes antidiabéticos para o tratamento de diabete mellitus
CO6311006A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ efectiva a dosis altas
NZ606825A (en) Methods and compositions for treating complement-associated disorders
CO6311007A2 (es) Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+, efectiva a dosis bajas
MXPA05011656A (es) Combinaciones para el tratamiento de enfermedades que implican proliferacion, migracion o apoptosis celulares de celulas de mieloma, o angiogenesis.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
JP2009545620A5 (es)
BR112012006283A2 (pt) formulação de adamts13 estabilizada, método para fabricar uma formulação de adamts13 estabilizada, kit, e métodos para tratar ou prevenir uma doença e para tratar ou previnir um enfarte
NI200800169A (es) Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor
UY32739A (es) Combinaciones de agentes quimioterápicos y antagonistas dll4 y sus usos en terapia del cáncer
CO6260078A2 (es) Metodo y tratamiento del trastorno por estres postraumatico mediante la administracion de un agente seleccionado entre benzodiazepina, un inhibidor (isrs) y otros

Legal Events

Date Code Title Description
FA Abandonment or withdrawal